The Hippo signaling pathway, initially discovered as a pathway that inhibits tissue growth in Drosophila, is mainly composed of three kinase cascades: MST1/2, LATS1/2, and Yap/TAZ. As research progressed, homologous genes of the Hippo signaling pathway were also identified in mammals, and they play a critical role in controlling organ size and other physiological functions. The Hippo signaling pathway mainly exerts its effects by regulating the nuclear translocation of Yap. When the upstream kinases of the Hippo signaling pathway are inactivated, Yap/TAZ becomes dephosphorylated and can enter the cell nucleus as a transcriptional co-activator, where it interacts with specific transcription factors to exert its effects. Previous studies on the Hippo-Yap signaling pathway have mainly focused on cell fate, metabolism, tumorigenesis, and the immune system. As research continues to deepen and the incidence of liver diseases increases, significant progress has been made in understanding the role of the Hippo signaling pathway in the occurrence and development of liver diseases. In this context, the authors discuss the involvement of the Hippo-Yap signaling pathway in various clinically common liver diseases, including cholestatic liver injury, liver ischemia-reperfusion injury, non-alcoholic fatty liver disease, alcoholic liver disease, acetaminophen-induced liver injury, liver fibrosis, and liver cancer.